"instanceType","uuid:ID","versionIdentifier","id","rationale"
"StudyVersion","9becaec1-8fdf-435c-a32f-797bc95b9c12","2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
